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ISSUE BRIEF
From 2010 to 2015, annual overdose deaths involving opioids in the 
United States increased by nearly 57%, with a notable rise in deaths 
attributed to synthetic opioids other than methadone (hereafter referred 
to as synthetic opioid overdose deaths), which rose from 3,007 to 9,580, 
an increase of 219%. Synthetic opioids are made from chemicals in a lab, 
and include such drugs as fentanyl, tramadol, and Demerol.TM
The dramatic rise in synthetic opioid overdose deaths has likely been driven 
primarily by a rise in deaths involving fentanyl,  which is manufactured 
legally for medical use, but can also be produced illicitly and sold on the 
illegal drug market – often mixed with or sold as heroin. The increase in 
synthetic opioid overdose deaths from 2010 to 2015 has had varying 
impacts on different regions of the United States; having disproportionately 
impacted the Midwest, Northeast, and some Southern states.2  
Increase in overdose deaths involving synthetic opioids other than methadone 
linked to increase in supply of fentanyl in PBSS states.
In this data brief, we compare trends in synthetic opioid 
overdose deaths in five PBSS states to trends in law enforcement 
drug reports for fentanyl in those states, as well to trends in the 
number of prescriptions of pharmaceutical fentanyl.
PBSS (Prescribing Rates)
The Prescription Behavior 
Surveillance System (PBSS) collects 
prescription drug monitoring 
program (PDMP) data from 12 states 
– California, Delaware, Florida, Idaho, 
Kentucky, Louisiana, Maine, Ohio, 
Texas, Virginia, Washington, and West 
Virginia – referred to in this report as 
PBSS states. The system uses these 
data to calculate aggregate indicators 
of controlled substance prescribing 
behaviors, such as the rate of opioids 
prescribed per 1,000 population and 
average dose prescribed.
NVSS (Overdose Deaths)
The National Vital Statistics System 
is an inter-governmental data 
sharing system that utilizes various 
forms of vital statistics for the entire 
population of the United States. 
The system involves coordination 
between the different state health 
departments and the National Center 
for Health Statistics.
NFLIS (Drug Reports)
The National Forensic Laboratory 
Information System (NFLIS) is 
a program administered by the 
Drug Enforcement Administration 
that systematically collects drug 
identification results from drug cases 
submitted for analysis to federal, 
state, and local forensic laboratories 
around the U.S.
Analysis was limited to five states based on their record of good to 
excellent reporting on death certificates of at least one specific drug 
involved in drug overdose deaths. These comparisons provide evidence 
for the dominant role of illicitly manufactured fentanyl (IMF) in the 
rise of synthetic opioid overdose deaths in several regions of the U.S., 
particularly in states east of the Mississippi River.
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FENTANYL: Overdoses On The Rise 
Fentanyl is a synthetic opioid approved for treating severe pain, such as advanced cancer pain. 
Illicitly manufactured fentanyl is the main driver of recent increases in synthetic opioid deaths.
Although prescription rates have 
fallen, overdoses associated with 
fentanyl have risen dramatically, 
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States See Sharp Rise in Overdose 
Death Rates Involving Synthetic 
Opioids other than Methadone
The national rate of synthetic opioid overdose 
deaths was at or below 1 per 100,000 from 2010 
through 2013, then more than tripled from 2013 
to 2015, reaching 3.1 per 100,000.1 This rapid rise 
is reflected in similar increases in synthetic opioid 
overdose death rates in several PBSS states located 
in the East, Midwest, and Appalachian regions of 
the country, including West Virginia, Ohio, Maine, 
and Virginia.  However, in one western state, 
Washington, a much lower and more stable rate 
of synthetic opioid overdose deaths was observed 
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Fentanyl Reports on the Rise
During 2010-2015, dramatic 
changes were also occurring 
in the illegal drug market. 
Data from the DEA’s National 
Forensic Laboratory Information 
System (NFLIS) indicate that 
drug submissions (drug exhibits 
submitted to laboratories for 
analysis) testing positive for 
fentanyl (fentanyl reports) rose 
dramatically in several PBSS states, 
particularly Ohio and Virginia. 
(Figure 2a). Fentanyl reports in 
Ohio increased from 56 in 2010 
to 4,009 in 2015. During the same 
time period, fentanyl reports in 























Rates of drug deaths involving synthetic opioids, 2010-2015, 







Annual rates of synthetic opioid overdose deaths rose dramatically in many, but not all, PBSS states during 2010-2015.
Source:  CDC Wonder online database, https://wonder.cdc.gov/, queried May 15, 2017
States shown in order of death rates in 2015.  Missing data for 2011-12 in Maine are due to low numbers of synthetic opioid overdose deaths 
(<20) in those years leading to unstable rates.  All states depicted have reporting percentages of at least 80% of death certificates with at least one 
specific drug involved in overdose deaths in 2010, with the exception of Ohio, whose percentages ranged from 76% to 79% during 2010-2012.  
Ohio data were included despite not meeting the 80% threshold because of numerous other sources that have corroborated the sharp rise in 
synthetic opioid overdose deaths that have occurred in Ohio beginning in 2014.2,16 
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Sudden increases in fentanyl reports also occurred in some of the other PBSS states during this time period, 
particularly West Virginia and Maine, though on a much smaller scale compared to Ohio and Virginia. (Note 
the vastly different scale of the vertical axis in Figure 2b). Washington state had a spike in fentanyl reports in 



















Number of Reported Law Enforcement Exhibits Testing Positive for Fentanyl in 







FIGURE 2B Annual fentanyl drug reports in the remaining PBSS states.
Prescription Fentanyl Rates Remain Steady
In contrast to the rising law enforcement fentanyl drug reports during 2010-2015, prescribing rates for 
pharmaceutical fentanyl in PBSS states remained fairly stable. In fact, one state with high numbers of drug 
submissions testing positive for fentanyl and high rates of synthetic opioid overdose deaths (Ohio) actually 
experienced decreasing levels of pharmaceutical fentanyl prescribing rates during this time period overall 
(see circle in Figure 3).



































Source: Prescription Behavior Surveillance 
System (PBSS), queried May 15, 2017
States shown in order of mean prescribing 
rate for the period from 2010 to 2015.  
The state of Washington was not able to 
provide prescription data for all years in 
this period.
*”LA” indicates long-acting, by far the most 
commonly prescribed formulation  
of fentanyl.
Source: NFLIS database, queried on 
June 26, 2017
States shown in order of numbers 
of submission testing positive for 
fentanyl in 2015.
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Overall, these data, along with other reports describing the geographic pattern of synthetic 
opioid overdose deaths versus law enforcement drug reports for fentanyl,2 suggest that illicitly 
manufactured fentanyl (IMF), as opposed to pharmaceutical fentanyl, is the main driver 
of the recent increase in deaths involving synthetic opioids other than methadone, and has 
disproportionately affected states located in the Midwest and Eastern regions of the U.S. Increasing 
numbers of synthetic opioid overdose deaths in states with increasing levels of fentanyl drug 
reports highlights the need for close collaboration between public health and public safety in order to 
optimize the response to the ongoing opioid overdose epidemic.
WHAT THIS MEANS
WHAT CAN BE DONE
The following recommendations can be found among those listed in CDC’s 
October 26, 2015 Health Advisory “Increases in Fentanyl Drug Confiscations and 
Fentanyl-related Overdose Fatalities.”
Preventing Overdoses with Naloxone
A vital means by which promoters of both public health and public safety can work together to respond to 
IMF overdose deaths is through the expanded use of naloxone. Naloxone is a safe and effective antidote to 
all opioid-related overdoses, including those involving fentanyl, and is a critical tool in preventing fatal opioid 
overdoses.3, 4  Depending on state and local laws, this medication can potentially be administered effectively by 
EMS, law enforcement,5 people at high risk for overdose,6 or family and friend bystanders who have obtained 
the medication.7
Health Care Providers
• Increase the amount of naloxone on hand for first responders such as law enforcement and  
EMS personnel.8
• Recognize and treat opioid overdose patients, with particular focus on how to respond to fentanyl  
and acetyl fentanyl overdose.8 
• Understand that multiple doses of naloxone may need to be administered per fentanyl overdose  
event because of the drug’s increased potency relative to other opioids.9
Harm Reduction Organizations
• Expand naloxone access to persons at risk for opioid-related overdose and their family members10 and 
train persons using drugs how to effectively administer naloxone.
• Provide take-home naloxone kits and encourage people who use heroin and/or misuse opioid 
analgesics—or know people that do—to carry them.
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Improving Detection of Fentanyl Outbreaks
Other critical steps can be taken by public health departments, medical 
examiners and coroners, and law enforcement to improve the detection of 
fentanyl outbreaks.
Public Health Departments
• Explore methods for more rapidly detecting drug overdose outbreaks, 
including fentanyl,11 by using existing surveillance systems such as 
medical examiner data, emergency medical services data, or near  
real-time emergency department data.
• In critical areas, consider asking emergency departments to report 
fatal and nonfatal opioid overdose cases within 48 hours.12
• Identify and track decedent demographics and risk factors, along with 
geographic concentrations of cases, to better inform public health 
surveillance and overdose prevention efforts.13
Medical Examiners/Coroners
• Screen specimens from fatal drug overdose deaths using an enzyme-
linked immunosorbent assay (ELISA test) with the capacity to detect 
fentanyl.
• Implement standardized mechanisms for determining cause of death 
and methods of reporting to ensure death reports are complete and 
accurate.14 
Law Enforcement
• Test drug samples seized or collected by law enforcement or found at 
the scene of death to detect fentanyl or fentanyl analogs.15
• Prioritize and expedite testing of drug samples taken from drug 
overdose scenes, if possible.
• Share data on fentanyl and fentanyl analogues drug reports with local 
health departments, coroners, and medical examiners.
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About PBSS: The Prescription 
Behavior Surveillance System 
(PBSS) provides epidemiological 
analyses of de-identified data from 
state prescription drug monitoring 
programs to help target and evaluate 
interventions aimed at reducing 
prescription drug abuse and 
diversion. For further information,  
see pdmpassist.org.
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